Camille L. Bedrosian net worth and biography

Camille Bedrosian Biography and Net Worth

Dr. Bedrosian joined Ultragenyx in January 2018 as Chief Medical Officer and Executive Vice President. In this role, she provides strategic leadership to the clinical development and translational research programs, and oversees global development functions including: Medical, Clinical, Development Operations, Regulatory, Biometrics/CORE, Drug Safety/Pharmacovigilance, and Patient Advocacy and Engagement.

Prior to joining Ultragenyx, Dr. Bedrosian served nearly a decade as Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals, Inc. Prior to Alexion, Dr. Bedrosian spent more than five years as the Chief Medical Officer for ARIAD Pharmaceuticals, Inc., and earlier she served in the Clinical Research and Development Department of Genetics Institute, Inc. (acquired by Wyeth, now part of Pfizer). Previously, Dr. Bedrosian was an Assistant Professor of Medicine at Duke University Medical Center and a member of the Duke Comprehensive Cancer Center, where she completed her residency in internal medicine and a fellowship in hematology and medical oncology.

Dr. Bedrosian serves on the Board of Directors of Rhythm Pharmaceuticals and Crinetics Pharmaceuticals.

Dr. Bedrosian earned an A.B., magna cum laude, in honors chemistry from Harvard University, an M.D. from Harvard Medical School, and an M.S. in biophysics from the Massachusetts Institute of Technology (MIT). She currently serves as a member of the MIT Corporation Visiting Committee for the Department of Biology.

What is Camille L. Bedrosian's net worth?: The estimated net worth of Camille L. Bedrosian is at least $6.67 million as of September 30th, 2024. Dr. Bedrosian owns 143,801 shares of Ultragenyx Pharmaceutical stock worth more than $6,672,366 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Bedrosian may own. Learn More about Camille L. Bedrosian's net worth.
How do I contact Camille L. Bedrosian?: The corporate mailing address for Dr. Bedrosian and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Camille L. Bedrosian's contact information.
Has Camille L. Bedrosian been buying or selling shares of Ultragenyx Pharmaceutical?: Camille L. Bedrosian has not been actively trading shares of Ultragenyx Pharmaceutical during the last quarter. Most recently, Camille L. Bedrosian sold 3,881 shares of the business's stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $45.25, for a transaction totalling $175,615.25. Following the completion of the sale, the executive vice president now directly owns 46,720 shares of the company's stock, valued at $2,114,080. Learn More on Camille L. Bedrosian's trading history.
Who are Ultragenyx Pharmaceutical's active insiders?: Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Eric Crombez (Chief Medical Officer and EVP), Mardi Dier (CFO), Matthew Fust (Director), Erik Harris (EVP), Howard Horn (CFO and EVP, Corporate Strategy), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?: During the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 91,799 shares worth more than $4,701,943.08. The most recent insider tranaction occured on October, 10th when CFO Howard Horn sold 7,465 shares worth more than $393,853.40. Insiders at Ultragenyx Pharmaceutical own 5.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.
Information on this page was last updated on 10/10/2024.

Camille L. Bedrosian Insider Trading History at Ultragenyx Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2023	Sell	3,881	$45.25	$175,615.25	46,720
1/30/2022	Sell	1,657	$66.30	$109,859.10
10/14/2021	Sell	359	$81.14	$29,129.26
9/1/2021	Sell	2,500	$100.03	$250,075.00
4/15/2021	Sell	5,000	$109.09	$545,450.00	44,139
1/30/2021	Sell	2,243	$140.36	$314,827.48
10/14/2020	Sell	262	$88.00	$23,056.00

Camille L. Bedrosian Buying and Selling Activity at Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $46.40

$44.90

$46.98

50 Day Range

MA: $53.80

$43.78

$59.36

2 Week Range

Now: $46.40

$37.02

$60.37

Volume

641,624 shs

Average Volume

965,546 shs

Market Capitalization

$4.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.